X4 Pharmaceuticals secures up to $150M senior debt facility

X4 Pharmaceuticals says it completed repayment of an existing loan facility and secured a senior debt facility with K2 HealthVentures of up to $150 million. The company expects to complete enrollment in its Phase 3 4WARD trial by year-end 2026 and deliver topline data in H1 2028.